Cambridge, USA-based EQRx, a biotech firm focused on developing lower-cost innovative medicines, has announced new data from a trial of its lung cancer candidate, sugemalimab. 15 September 2021
Following the transformational merger with DCprime in December 2020, Swedish biotech Immunicum now aims to become a global leader in off-the-shelf, allogeneic cell therapies, using its expertise in dendritic cell (DC) biology, comment analysts at Edison Investment Research. 15 September 2021
Canadian biotech AbCellera yesterday announced it has acquired TetraGenetics, a USA-based company with a proprietary platform for generating recombinant human ion channels and other transmembrane proteins. 14 September 2021
AbbVie and Regenxbio today announced an ophthalmic partnership, worth a potential $1.75 billion, resulting in a near 23% leap to $40.61 in the latter’s share price by mid-morning. 13 September 2021
UK endocrine diseases specialist Diurnal Group today announced the commercial launch of Efmody (hydrocortisone modified-release hard capsules) in the UK as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH). 13 September 2021
US drug developer Apellis Pharmaceuticals was upbeat about clinical trial results for its pegcetacoplan, but investors thought otherwise, sending the firm’s shares down 32% to $38.00 in after hours on Thursday. 10 September 2021
Twist Bioscience Corp saw its shares increase 6% to $117.93 today, after it announced a broad-based research collaboration with German family-owned drug major Boehringer Ingelheim to use Twist’s proprietary antibody libraries to discover therapeutic antibodies against multiple targets provided by Boehringer Ingelheim. 9 September 2021
Shares of Centessa Pharmaceuticals were up 17.6% at $24.76 in early trading today after, together with subsidiary ApcinteX, it announced positive top-line results from the Phase IIa part of AP-0101, the six-month repeat dose portion of its ongoing first-in-human proof-of-concept study evaluating SerpinPC in severe hemophilia A and B patients. 9 September 2021
Dutch biotech firm ProQR Therapeutics has inked a global licensing and research collaboration with Eli Lilly, worth over a billion dollars in the best case scenario. 9 September 2021
Sino-American company Brii Birosciences today announced that it is committing an additional $100 million to advance global regulatory filings and commercial efforts for its investigational SARS-CoV-2 (virus that causes COVID-19) combination therapy, BRII-196/BRII-198. 7 September 2021
Lumevoq (lenadogene nolparvovec) has been granted Promising Innovative Medicine (PIM) designation by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). 7 September 2021
Swedish biotech pairing Alligator Bioscience and Scandion Oncology have concluded a research collaboration, describing its outcome as positive. 2 September 2021
Precision BioSciences and UK biotech Tiziana Life Sciences have entered an exclusive license agreement to explore Tiziana's foralumab, a fully human anti-CD3 monoclonal antibody (MAb), as an agent to induce tolerance of allogeneic CAR T-cells to potentially improve the clinical outcome of CAR-T cell therapy. 2 September 2021
Brukinsa (zanubrutinib) has received approval from the US Food and Drug Administration (FDA) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). 2 September 2021
Chinese biopharma firm Innovent Biologics and US biotech Bolt Biotherapeutics have announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate (ISAC) candidates. 31 August 2021
Shares of Belgian cell therapy developer Bone Therapeutics tumbled 34.6% 1.73 euros by early afternoon trading, after the company announced that the Phase III knee osteoarthritis study with its enhanced viscosupplement JTA-004 did not meet the primary and consequently the key secondary endpoints. 30 August 2021
Following a positive opinion from the European Medicines Agency’s human health committee in June, the European Commission (EC) has rubber-stamped its marketing authorization for Voxzogo (vosoritide), a once daily injection to treat achondroplasia in children from the age of two until growth plates are closed, which occurs after puberty when children reach final adult height. 28 August 2021
USA-based oncology specialist Sesen Bio, in a filing with the US Securities and Exchange Commission (SEC), revealed that it has withdrawn its marketing authorization application (MAA) to the European Medicines Agency for Vysyneum (oportuzumab monatox) for the treatment of Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). 27 August 2021
Sino-American company Brii Biosciences has announced positive data from the ACTIV-2 Phase III trial evaluating the combination of BRII-196 and BRII-198 in non-hospitalized COVID-19 patients. 26 August 2021
US drugmaker Eagle Pharmaceuticals has entered into a worldwide licensing agreement with Swiss biotech Combioxin for the commercial rights to CAL02, an antitoxin agent ready for Phase IIb/III development for the treatment of severe pneumonia in combination with traditional antibacterial drugs. 26 August 2021
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024